Benzofuran-based estrogen receptor α modulators as anti-cancer therapeutics: In silico and experimental studies

Current Medicinal Chemistry

Volumn 20, Issue 22, 2013, Pages 2820-2837

  Leow, Min Li ^a   Chin, Hui Li Christina ^b   Yu, Peggy Shuang ^a   Pasunooti, Kalyan Kumar ^a   Tay, Raymond Xu Zhan ^a   Zhang, Dawei ^a   Yoon, Ho Sup ^b   Liu, Xue Wei ^a  

^a Nanyang Technological University   (Singapore)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Apoptosis; Benzofuran; Estrogen receptor; Proliferation; Structure activity relationships

Indexed keywords

ANTINEOPLASTIC AGENT; BENZOFURAN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; HYDROXYL GROUP; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL STRAIN MCF 7; COMPUTER MODEL; CYTOTOXICITY TEST; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; EXPERIMENTAL STUDY; FEMALE; HUMAN; HUMAN CELL; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOFURANS; CELL LINE, TUMOR; CELL SURVIVAL; COMPUTER SIMULATION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; HUMANS; MODELS, MOLECULAR;

EID: 84880285712     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320220007     Document Type: Article

References (51)

1. Howlader N; Noone AM; Krapcho M; Neyman N; Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer. gov/csr/1975-2009-pops09/(Accessed Feb 6, 2013).
2. Kuiper, G. G. J. M.; Enmark, E.; Pelto-Huikko, M.; Nilsson, S.; Gustafsson, J. Å. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 1996, 93, 5925-5930.
3. Pettersson, K.; Gustafsson, J. A. Role of estrogen receptor beta in estrogen action. Annu. Rev. Physiol. 2001, 63, 165-192.
4. Jordan, V. C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J. Med. Chem. 2003, 46, 883-908.
5. Jordan, V. C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J. Med. Chem. 2003, 46, 1081-1111.
6. Maximov, P. Y.; Myers, C. B.; Curpan, R. F.; Lewis-Wambi, J. S.; Jordan, V. C. Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen. J. Med. Chem. 2010, 53, 3273-3283.
7. Anstead, G. M.; Carlson, K. E.; Katzenellenbogen, J. A. The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 1997, 62, 268-303.
8. Fink, B. E.; Mortensen, D. S.; Stauffer, S. R.; Aron, Z. D.; Katzenellenbogen, J. A. Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens. Chem. Biol. 1999, 6, 205-219.
9. Mortensen, D. S.; Rodriguez, A. L.; Carlson, K. E.; Sun, J.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Synthesis and biological evaluation of a novel series of furans: Ligands selective for estrogen receptor α. J. Med. Chem. 2001, 44, 3838-3848.
10. Stauffer, S. R.; Huang, Y.; Coletta, C. J.; Tedesco, R.; Katzenellenbogen, J. A. Estrogen pyrazoles: Defining the pyrazole core structure and the orientation of substituents in the ligand binding pocket of the estrogen receptor. Bioorg. Med. Chem. 2001, 9, 141-150.
11. Zhou, H. B.; Comninos, J. S.; Stossi, F.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Synthesis and evaluation of estrogen receptor ligands with bridged oxabicyclic cores containing a diarylethylene motif: Estrogen antagonists of unusual structure. J. Med. Chem. 2005, 48, 7261-7274.
12. Zhou, H. B.; Sheng, S.; Compton, D. R.; Kim, Y.; Joachimiak, A.; Sharma, S.; Carlson, K. E.; Katzenellenbogen, B. S.; Nettles, K. W.; Greene, G. L.; Katzenellenbogen, J. A. Structure-guided optimization of estrogen receptor binding affinity and antagonist potency of pyrazolopyrimidines with basic side chains. J. Med. Chem. 2007, 50, 399-403.
13. Gruber, C.; Gruber, D. Bazedoxifene (Wyeth). Curr. Opin. Invest. Dr. 2004, 5, 1086-1093.
14. De Angelis, M.; Stossi, F.; Carlson, K. A.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Indazole estrogens: Highly selective ligands for the estrogen receptor α. J. Med. Chem. 2005, 48, 1132-1144.
15. Jorgensen, A. S.; Jacobsen, P.; Christiansen, L. B.; Bury, P. S.; Kanstrup, A.; Thorpe, S. M.; Narum, L.; Wassermann, K. Synthesis and estrogen receptor binding affinities of novel pyrrolo[2,1,5-cd]indolizine derivatives. Bioorg. Med. Chem. Lett. 2000, 10, 2383-2386.
16. Palkowitz, A. D.; Glasebrook, A. L.; Thrasher, K. J.; Hauser, K. L.; Short, L. L.; Phillips, D. L.; Muehl, B. S.; Sato, M.; Shetler, P. K.; Cullinan, G. J.; Pell, T. R.; Bryant, H. U. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]benzo[b] thiophene: A novel, highly potent, selective estrogen receptor modulator. J. Med. Chem. 1997, 40, 1407-1417.
17. Teo, C. C.; Kon, O. L.; Sim, K. Y.; Ng, S. C. Synthesis of 2-(pchlorobenzyl)-3-aryl-6-methoxybenzofurans as selective ligands for antiestrogen-binding sites. Effects on cell proliferation and cholesterol synthesis. J. Med. Chem. 1992, 35, 1330-1339.
18. Harris, H. A.; Albert, L. M.; Leathurby, Y.; Malamas, M. S.; Mewshaw, R. E.; Miller, C. P.; Kharode, Y. P.; Marzolf, J.; Komm, B. S.; Winneker, R. C.; Frail, D. E.; Henderson, R. A.; Zhu, Y.; Keith Jr, J. C. Evaluation of an estrogen receptor-k agonist in animal models of human disease. Endocrinology 2003, 144, 4241-4249.
19. Barlaam, B.; Bernstein, P.; Dantzman, C.; Warwick, P. Preparation of benzoxazoles and benzothiazoles as selective ligands for human ?-estrogen receptor. PCT Int. Appl (Astrazeneca AB, Sweden) WO 2002, 71.
20. Kirilmis, C.; Ahmedzade, M.; Servi, S.; Koca, M.; Kizirgil, A.; Kazaz, C. Synthesis and antimicrobial activity of some novel derivatives of benzofuran: Part 2. The synthesis and antimicrobial activity of some novel 1-(1-benzofuran-2-yl)-2-mesitylethanone derivatives. Eur. J. Med. Chem. 2008, 43, 300-308.
21. Ebiike, H.; Masubuchi, M.; Liu, P.; Kawasaki, K.; Sogabe, S.; Hayase, M.; Fujii, T.; Sakata, K.; Shindoh, H.; Shiratori, Y.; Aoki, Y.; Ohtsuka, T.; Shimma, N. Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal Nmyristoyltransferase. Part 2. Bioorg. Med. Chem. Lett. 2002, 12, 607-610.
22. Maeda, S.; Masuda, H.; Tokoroyama, T. Studies on the preparation of bioactive lignans by oxidative coupling reaction, III. Synthesis of polyphenolic benzofuran and coumestan derivatives by oxidative coupling reaction of methyl (E)-3-(4-hydroxy-2-methoxyphenyl)propenoate and their inhibitory effect on lipid peroxidation. Chem. Pharm. Bull. 1994, 42, 2536-2545.
23. Lin, P.; Li, S.; Wang, S.; Yang, Y.; Shi, J. A nitrogen-containing 3-alkyl-1,4-benzoquinone and a gomphilactone derivative from Embelia ribes. J. Nat. Prod. 2006, 69, 1629-1632.
24. Hayakawa, I.; Shioya, R.; Agatsuma, T.; Furukawa, H.; Sugano, Y. Thienopyridine and benzofuran derivatives as potent anti-tumor agents possessing different structure-activity relationships. Bioorg. Med. Chem. Lett. 2004, 14, 3411-3414.
25. Da Silva, A. J. M.; Melo, P. A.; Silva, N. M. V.; Brito, F. V.; Buarque, C. D.; De Souza, D. V.; Rodrigues, V. P.; Poças, E. S. C.; Noël, F.; Albuquerque, E. X.; Costa, P. R. R. Synthesis and preliminary pharmacological evaluation of coumestans with different patterns of oxygenation. Bioorg. Med. Chem. Lett. 2001, 11, 283-286.
26. Su, B. N.; Cuendet, M.; Hawthorne, M. E.; Kardono, L. B. S.; Riswan, S.; Fong, H. H. S.; Mehta, R. G.; Pezzuto, J. M.; Kinghorn, A. D. Constituents of the bark and twigs of Artocarpus dadah with cyclooxygenase inhibitory activity. J. Nat. Prod. 2002, 65, 163-169.
27. Rida, S. M.; El-Hawash, S. A. M.; Fahmy, H. T. Y.; Hazzaa, A. A.; El-Meligy, M. M. M. Synthesis of novel benzofuran and related benzimidazole derivatives for evaluation of in vitro anti-HIV-1, anticancer and antimicrobial activities. Arch. Pharm. Res. 2006, 29, 826-833.
28. Cheng, X. M.; Liu, X. W. Microwave-enhanced one-pot synthesis of diversified 3-acyl-5-hydroxybenzofuran. J. Comb. Chem. 2007, 9, 906-908.
29. Irwin, J. J.; Shoichet, B. K. ZINC: A free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 2005, 45, 177-182.
30. Glide, version 4.5, Schrödinger LLC, New York, NY, 2007.
31. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening. J. Med. Chem. 2004, 47, 1750-1759.
32. Perola, E.; Walters, W. P.; Charifson, P. S. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins 2004, 56, 235-249.
33. Englebienne, P.; Moitessier, N. Docking ligands into flexible and solvated macromolecules. 4. Are popular scoring functions accurate for this class of proteins? J. Chem. Inf. Model. 2009, 49, 1568-1580.
34. Bytheway, I.; Cochran, S. Validation of Molecular Docking Calculations Involving FGF-1 and FGF-2. J. Med. Chem. 2004, 47, 1683-1693.
35. Gadakar, P. K.; Phukan, S.; Dattatreya, P.; Balaji, V. N. Pose prediction accuracy in docking studies and enrichment of actives in the active site of GSK-3β J. Chem. Inf. Model. 2007, 47, 1446-1459.
36. CombiGlide, version 1.5, Schrödinger LLC, New York, NY, 2007.
37. QM-Polarized Ligand Docking, Schrödinger LLC, New York, NY, 2007.
38. Pei, L. X.; Li, Y. M.; Bu, X. Z.; Gu, L. Q.; Chan, A. S. C. One-pot synthesis of 5,6-dihydroxylated benzo[b]furan derivatives. Tetrahedron Lett. 2006, 47, 2615-2618.
39. Liang, Z.; Hou, W.; Du, Y.; Zhang, Y.; Pan, Y.; Mao, D.; Zhao, K. Oxidative aromatic C-O bond formation: Synthesis of 3-functionalized benzo[b]furans by FeCl3-mediated ring closure of a-Aryl ketones. Org. Lett. 2009, 11, 4978-4981.
40. Ekena, K.; Weise, K. E.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S. Different residues of the human estrogen receptor are involved in the recognition of structurally diverse estrogens and antiestrogens. J. Biol. Chem. 1997, 272, 5069-5075.
41. Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engström, O.; Öhman, L.; Greene, G. L.; Gustafsson, J. Å.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389, 753-758.
42. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95, 927-937.
43. Tanenbaum, D. M.; Wang, Y.; Williams, S. P.; Sigler, P. B. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc. Natl. Acad. Sci. USA 1998, 95, 5998-6003.
44. Pike, A. C. W.; Brzozowski, A. M.; Hubbard, R. E.; Bonn, T.; Thorsell, A. G.; Engström, O.; Ljunggren, J.; Gustafsson, J. A.; Carlquist, M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 1999, 18, 4608-4618.
45. Fang, H.; Tong, W.; Shi, L. M.; Blair, R.; Perkins, R.; Branham, W.; Hass, B. S.; Xie, Q.; Dial, S. L.; Moland, C. L.; Sheehan, D. M. Structure-Activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. Chem. Res. Toxicol. 2001, 14, 280-294.
46. Wolohan, P.; Reichert, D.E. CoMFA and docking study of novel estrogen receptor subtype selective ligands. J. Comput. Aided Mol. Des. 2003, 17, 313-328.
47. Barrett, I.; Meegan, M. J.; Hughes, R. B.; Carr, M.; Knox, A. J. S.; Artemenko, N.; Golfis, G.; Zisterer, D. M.; Lloyd, D. G. Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators. Bioorg. Med. Chem. 2008, 16, 9554-9573.
48. Weng, S. C.; Kashida, Y.; Kulp, S. K.; Wang, D.; Brueggemeier, R. W.; Shapiro, C. L.; Chen, C. S. Sensitizing estrogen receptornegative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol. Cancer Ther. 2008, 7, 800-808.
49. Fattman, C. L.; An, B.; Sussman, L.; Dou, Q. P. p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen-induced apoptosis in human breast carcinoma cells. Cancer Lett. 1998, 130, 103-113.
50. Gelmann, E. P. Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: New tricks for an old dog? J. Natl. Cancer Inst. 1996, 88, 224-225.
51. Peng, K-W.; Wang, H.; Qin, Z.; Wijewickrama, G.T.; Lu, M.; Wang, Z.; Bolton, J.L.;Thatcher, G.R.J. Chem. Biol. 2009, 4, 1039.